As our Numerof 2026 U.S. Health Insurance Outlook infographic illustrates, the story for health insurance continues to be about dramatically changing roles and relationships. Payers will continue to engage in new and different ways with providers, consumers, employers, regulators, medical device makers and pharmaceutical manufacturers. All this will come in the context of significant political and regulatory uncertainty. Reimbursement pressures at a federal level challenge the viability of some markets.

Competition will continue to intensify, as new entrants (including delivery organizations) seek to bypass insurers via DTC and employer partnerships. New market entrants will use technology to minimize friction between the consumer and the payer and/or care delivery, redefining the healthcare delivery process as they do so. As deductibles and copays increase, and as regulation forces more transparency, consumers continue to make decisions as price-conscious healthcare shoppers. Engaging them will be more critical than ever. Meanwhile, employers seeking better outcomes at lower cost will engage in more direct contracting for bundled services in areas such as orthopedics, oncology and cardiac care, or even for all care on a PMPM basis.

Among hospital systems and IDNs, consolidation will continue to create challenges in holding down rates and improving quality of care outcomes. Now that roughly 80% of physicians are employed by the hospitals for which they work, physicians and hospitals have become increasingly aligned. Data sharing and distilling insights continues to grow in its importance. Moving providers toward new payment models and risk assumption will require active engagement by payers. Physician employment will continue and growing access will put more pressure on network adequacy.

Tension with pharmaceutical manufacturers over high priced drugs will continue, creating openings for new formulary and pricing approaches. MFN policies create uncertainty around the future of pricing as state and federal legislation put pressure on PBM spread pricing and pharmacy steerage. Insurers’ integration with PBMs raises concern among drug-makers about steerage, access and cost. Nevertheless, opportunities for collaboration in areas such as data sharing and risk-based contracting will grow for pharmaceutical and medical device manufacturers alike. National payers continue to fund new collaborations and to accelerate M&A activity across industry verticals – acquiring care delivery and tools to improve consumer engagement.

Given this outlook, what’s next? We recommend these key action steps:

• Demonstrate value tangibly to plan sponsors and members, with a focus on
  total cost of care.
• Engage with consumers differently to reduce membership churn and gain share
  in new markets.
• Identify providers that can assume accountability and risk.
• Actively engage providers to improve outcomes, reduce cost, and increase value.
• Develop analytic and influence capabilities required for success in risk-based models. Evaluate the utility of AI.

At Numerof & Associates, we support health insurance companies in achieving these key action steps for success in today’s evolving healthcare landscape. From competitive strategy and alliance development to implementation of new payment and network models, we have solutions. Read more about our perspectives and solutions for healthcare insurance and see our case studies.

Need critical insights across the healthcare sector? Check out our 2026 outlook infographics for healthcare delivery, medical devices and diagnostics, and pharmaceuticals.